

What is claimed:

1. A method of treating a pediatric subject infected with an HIV virus comprising administering to the subject:
25 mg or less of a non-nucleoside reverse transcriptase inhibitor that is rilpivirine, or
5 an equivalent amount of a pharmaceutically acceptable salt of rilpivirine, once daily;
wherein the subject weighs 11 kg or more; is treatment experienced; and was administered a first anti-retroviral regimen that has been discontinued;
and
10 wherein the subject exhibits a viral load of less than or equal to 50 copies of HIV virus particles per mL of blood plasma ($\leq 50\text{c/mL}$) after at least 24 weeks of the once-daily administration of the rilpivirine, or equivalent amount of the pharmaceutically acceptable salt of rilpivirine.
- 15 2. The method of claim 1, wherein the subject is administered a pharmaceutically acceptable salt of rilpivirine.
3. The method of claim 1 or claim 2, wherein the pharmaceutically acceptable salt of rilpivirine is the hydrochloride salt of rilpivirine.
4. The method of any one of the preceding claims, further comprising administering to the pediatric subject dolutegravir, tenofovir, tenofovir disoproxil fumarate, tenofovir
20 alafenamide, emtricitabine, or a combination thereof.
5. The method of any one of the preceding claims, wherein the pediatric subject is ≥ 2 to < 12 years.
6. The method of any one of the preceding claims, wherein the pediatric subject has a body weight of < 25 kg.
- 25 7. The method of any one of the preceding claims, wherein the pediatric subject has a body weight of ≤ 70 kg.
8. The method of any one of the preceding claims, wherein the pediatric subject exhibits a viral load of less than or equal to 50 copies of HIV virus particles per mL of blood

plasma (≤ 50 c/mL) prior to the once-daily administration of the rilpivirine, or equivalent amount of the pharmaceutically acceptable salt of rilpivirine.

9. The method of any one of the preceding claims, wherein the HIV virus is HIV-1.
10. The method of any one of the preceding claims, wherein the 25 mg or less of a non-nucleoside reverse transcriptase inhibitor that is rilpivirine, or the equivalent amount of the pharmaceutically acceptable salt of rilpivirine, is administered as a single unit dosage form.
11. The method of any one of claims 1 to 8, wherein the 25 mg or less of a non-nucleoside reverse transcriptase inhibitor that is rilpivirine, or the equivalent amount of the pharmaceutically acceptable salt of rilpivirine, is administered in multiple single unit dosage forms.
12. The method of any one of the preceding claims, wherein the subject exhibits a viral load of less than or equal to 50 copies of HIV-1 virus particles per mL of blood plasma (≤ 50 c/mL) after at least 48 weeks of once daily administration of the rilpivirine, or the pharmaceutically acceptable salt of rilpivirine.